Репозиторий Университета

© 2020 The Author(s) Patients with cancer undergoing chemotherapy are at risk of thrombocytopenia. The co-incidence of cancer-associated venous thromboembolism (VTE) and thrombocytopenia is a frequent complication in patients with cancer. Especially in certain tumour entities at high VTE risk, chemotherapeutic agents with myelosuppressive effects are part of the standard of care. The management of cancer-associated VTE in the setting of chemotherapy-induced thrombocytopenia is challenging, in the absence of evidence from high-quality studies. Thrombocytopenia is associated with both increased risk of recurrent VTE and risk of bleeding during anticoagulation. In this case-based concise review, we aimed at summarizing available literature and expert consensus guidance on the treatment of cancer-associated VTE in patients with chemotherapy-induced thrombocytopenia.

© 2018 Dynasty Publishing House. All rights reserved. Thrombocytopenia (TCP) includes a huge range of diseases and syndromes with different causes and pathogenetic mechanisms. TCP is defined when platelet count less than 150 × 109/L. the Diagnostic search when TCP should begin with the establishment of a pathogenic variant with subsequent verification of the main reasons for TCP. This allows you to select pathogenetic therapy of the disease (glucocorticoids, immunosuppressants, anticoagulants) and to influence the basic process.